Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis

Table 2 In vivo hemodynamic data of the four treatment groups

Parameter	Control	OVX + CCl4	OVX + CCl4 + DPN	OVX + CCl4 + DPN + PHTPP
PP (mmHg)	7.5 ± 1.1	14.9 ± 1.6a,c	11.0 ± 1.3a	14.6 ± 1.5a,c
CO (mL/min per 100 g)	19.3 ± 2.4	32.2 ± 5.0a,c	25.7 ± 4.0a	31.4 ± 5.4a,c
MAP (mmHg)	120.6 ± 14.2	82.1 ± 12.2a	95.7 ± 14.0a	89.5 ± 13.3a
TPR (mmHg/mL/min per 100 g)	6.0 ± 0.9	2.6 ± 0.3a	3.1 ± 0.7a	2.9 ± 0.6a
PVI (mL/min per 100 g)	2.1 ± 0.3	4.8 ± 0.8a,c	3.0 ± 0.4a	4.4 ± 0.6a,c
SVR (mmHg/mL/min per 100 g)	55.5 ± 8.5	15.0 ± 2.3a,c	31.7 ± 3.7a	16.8 ± 1.5a,c
PSS (%)	0.2 ± 0.1	50.5 ± 6.3a,c	27.9 ± 4.9a	48.1 ± 6.1a,c
IHVR (mmHg/mL/min per 100 g)	1.5 ± 0.2	3.2 ± 0.6a,c	2.2 ± 0.3a	3.0 ± 0.5a,c

^aP < 0.05 vs control group; ^bP < 0.05 vs DPN group. OVX: Ovariectomized; SVR: Systemic vascular resistance; DPN: Diarylpropionitrile.